However, it is clearly necessary to prospectively evaluate whether a change in the FABP4 value indeed reflects conditions of metabolic syndrome and atherosclerosis and predicts long-term cardiovascular outcomes in patients regardless of ESRD. This evidence concerns the gene FABP4 and metabolic syndrome.